- Home
- PGZ vs BEAT Comparison
PGZ vs BEAT Comparison
Compare PGZ & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- BEAT
- Stock Information
- Founded
- PGZ 2012
- BEAT 2015
- Country
- PGZ United States
- BEAT United States
- Employees
- PGZ N/A
- BEAT 20
- Industry
- PGZ Investment Managers
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- PGZ Finance
- BEAT Technology
- Exchange
- PGZ Nasdaq
- BEAT Nasdaq
- Market Cap
- PGZ 71.0M
- BEAT 66.1M
- IPO Year
- PGZ N/A
- BEAT 2021
- Fundamental
- Price
- PGZ $10.53
- BEAT $2.48
- Analyst Decision
- PGZ
- BEAT Buy
- Analyst Count
- PGZ 0
- BEAT 1
- Target Price
- PGZ N/A
- BEAT $8.00
- AVG Volume (30 Days)
- PGZ 23.0K
- BEAT 94.1K
- Earning Date
- PGZ 01-01-0001
- BEAT 11-07-2024
- Dividend Yield
- PGZ 12.26%
- BEAT N/A
- EPS Growth
- PGZ N/A
- BEAT N/A
- EPS
- PGZ N/A
- BEAT N/A
- Revenue
- PGZ N/A
- BEAT N/A
- Revenue This Year
- PGZ N/A
- BEAT N/A
- Revenue Next Year
- PGZ N/A
- BEAT N/A
- P/E Ratio
- PGZ N/A
- BEAT N/A
- Revenue Growth
- PGZ N/A
- BEAT N/A
- 52 Week Low
- PGZ $8.46
- BEAT $1.06
- 52 Week High
- PGZ $10.59
- BEAT $3.39
- Technical
- Relative Strength Index (RSI)
- PGZ 40.33
- BEAT 54.94
- Support Level
- PGZ $10.36
- BEAT $2.33
- Resistance Level
- PGZ $10.72
- BEAT $2.70
- Average True Range (ATR)
- PGZ 0.14
- BEAT 0.19
- MACD
- PGZ -0.01
- BEAT -0.00
- Stochastic Oscillator
- PGZ 27.97
- BEAT 54.17
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.